Coronary revascularization in patients with type 2 diabetes and results of the BARI 2D trial

Coronary Artery Disease

Volumn 21, Issue 3, 2010, Pages 189-198

  Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Acute coronary syndromes; BARI 2D; CABG; Clinically stable coronary disease; Coronary artery bypass grafting; Diabetes; Percutaneous coronary intervention; STEMI

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; INSULIN; METFORMIN; ROSIGLITAZONE;

BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETIC PATIENT; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERGLYCEMIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951296077     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3283383ebe     Document Type: Review

References (124)

1. Santayana G. Life of reason, reason in common sense. Scribner's Magazine 1905; 2:284.
2. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
3. Sobel BE. A perspective on the development of coronary revascularization. Coron Artery Dis (in press).
4. Haller JD, Olearchyk AS. Cardiology's 10 greatest discoveries. Tex Heart Inst J 2002; 29:342-344.
5. Nirav J, Mehta MD, Khan IA. Cardiology's 10 greatest discoveries of the 20th century. Tex Heart Inst J 2002; 29:164-171.
6. Favaloro RG. Direct myocardial revascularization: a 10 year journey myths and realities. Am J Cardiol 1979; 43:109-129.
7. Coronary Artery Surgery Study (CASS). A randomized trial of coronary artery bypass surgery. Survival data. Circulation 1983; 68:939-950.
8. European Coronary Surgery Study Group. Coronary-artery bypass surgery in stable angina pectoris: survival at two years. Lancet 1979; 1:889-893.
9. Varnauskas E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med 1988; 319:332-337.
10. Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J Jr, Braunwald E. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 1971; 43:67-82.
11. Braunwald E. Shattuck lecturer - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337:1360-1369.
12. Gogo P, Dauerman HL, Sobel BE. Prompt reperfusion: the linchpin of treatment for ST elevation myocardial infarction (STEMI). In: Brown D, Jeremias A, editors. Cardiac intensive care. 2nd ed. Philadelphia: Elsevier; 2009 (in press).
13. Sobel BE, Bresnahan GF, Shell WE, Yoder RD. Estimation of infarct size in man and its relation to prognosis. Circulation 1972; 46:640-648.
14. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303:897-902.
15. Chazov EL, Matveeva LS, Mazaev AV. Intracoronary administration of fibrinolysis in acute myocardial infarction. Ter Arkh 1976; 48:8-19.
16. Rentrop P, Blanke H, Karsch KR,Weigand V, Kostering H, Rahiv G, et al. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 1979; 2:354-357.
17. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarcto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1:397-402.
18. Sobel BE. Coronary thrombolysis: background and factors underlying its emergence. In: Sobel BE, Collen D, editors. Coronary thrombolysis in perspective. New York: Marcel Dekker; 1993. pp. 1-11.
19. European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction. Streptokinase in acute myocardial infarction. N Engl J Med 1979; 301:797-802.
20. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase 1 findings. N Engl J Med 1985; 312:932-936.
21. Arnold AE, Simoons ML, Van de Werf F, de Bono DP, Lubsen J, Tijssen JG, et al. The European Cooperative Study Group. Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up. Circulation 1992; 86:111-120.
22. Lenderink T, Simoons ML, Van Es GA, Van deWerf F, Verstraete M, Arnold AE. The European Cooperative Study Group. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation 1995; 92:1110-1116.
23. Lee L, Bates ER, Pitt B,Walton JA, Laufer N, O'Neill WW. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 1988; 78:1345-1351.
24. O'Neill W, Timmis GC, Bourdillon PD, Lai P, Ganghadarhan V,Walton J Jr, et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med 1986; 314:812-818.
25. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361:13-20.
26. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993; 328:680-684.
27. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al.; The Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328:673-679. (Pubitemid 23073368)
28. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336:1621-1628.
29. Dauerman H, Sobel BE, editors. Pharmacoinvasive therapy in acute myocardial infarction. New York: Marcel Dekker; 2005.
30. Jaffe R, Halon DA, Karkabi B, Goldstein J, Rubinstein R, Flugelman MY, Lewis BS. Thrombolysis followed by early revascularization: an effective reperfusion strategy in real world patients with ST-elevation myocardial infarction. Cardiology 2007; 107:329-336.
31. Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, et al.; Goodman SG for the TRANSFER-AMI Trial Investigators. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009; 360:2705-2718.
32. Boden WE, O'Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zobie RG, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQUISH) Trial Investigators. N Engl J Med 1998; 338:1785-1792.
33. Lange RA, Hillis LD. Use and overuse of angiography and revascularization for acute coronary syndromes. N Engl J Med 1998; 338:1838-1839.
34. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomized multicentre study. Lancet 1999; 354:708-715.
35. Mehta SR, Granger CB, Boden WE, Steg PG, Bassant J-P, Faxon DP, et al.; for the TIMACS Investigators. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009; 360:2165-2175.
36. Schlant RC. Reperfusion in acute myocardial infarction. Circulation 1994; 90:2091-2102.
37. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes. An analysis from the ACUITY trial. J Am Coll Cardiol 2007; 49:1362-1368.
38. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: executive summary. Circulation 2007; 116:803-877.
39. Montalescot G, Cayla G, Collet JP, Elhadad S, Beygui F, Le Breton H, et al. Immediate versus delayed intervention for acute coronary syndromes: a randomized clinical trial. JAMA 2009; 302:947-954.
40. Serruys PW, Morice M-C, Kappentein AP, Colombo A, Holmes DR, Mack MJ, et al.; for the SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360:961-972.
41. Garg S, Serruys PW. Meditations on secondary revascularization in the aftermath of the SYNTAX trial. Eurolntervention 2009; 5 (Suppl D):D14-D20.
42. RITA-2 Trial Participants. Coronary angioplasty versus medical therapy for angina: The second Randomised Intervention Treatment of Angina (RITA-1) trial. Lancet 1997; 350:461-468.
43. Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KAA, Julian DG, Chamberlain DA; for the Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Seven-year outcome in the RITA-2 trial: Coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003; 42:1161-1170.
44. King SB III. Five-year follow-up of the medicine, angioplasty, or surgery study (MASS-II). Circulation 2007; 115:1064-1066.
45. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al.; for the COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356:1503-1516.
46. Holmes DR Jr, Gersh BJ, Whitlow P, King SB III, Dove JT. Percutaneous coronary intervention for chronic stable angina: a reassessment. J Am Coll Cardiol Cardiovasc Interv 2008; 1:34-43.
47. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet 2009; 373:911-918.
48. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina. Circulation 2007; 116:2762-2772.
49. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. Circulation 2008; 117:296-329.
50. Eagle KA, Nallamothu BK, Mehta RH, Granger CB, Steg PG,Van deWerf F, et al.; Fox KAA for the Global Registry of Acute Coronary Events (GRACE) Investigators. Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. Eur Heart J 2008; 29:609-617.
51. King SB III, Kosinski AS, Guyton RA, Lembo NJ,Weinstraub WS; for the Emory Angioplasty Versus Surgery Trial (EAST) Investigators. Eight-year mortality in the Emory Angioplasty Versus Surgery Trial (EAST). J Am Coll Cardiol 2000; 35:1116-1121.
52. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335:217-225.
53. Mollinedo PM. Coronary artery revascularization in diabetes. The CARDia trial. ESC. 2008; Abstract 1694, Hot Line Update II.
54. Sobel BE, Schneider DJ. Cardiovascular complications in diabetes mellitus. Curr Opin Pharmacol 2005; 5:143-148.
55. PocockSJ, HendersonRA, RickardsAF,Hampton JR, KingSB III, HammCW, et al. Meta-analysis of randomized trials comparing coronary angioplasty with bypass surgery. Lancet 1005; 346:1184-1189.
56. Hlatky MA, Bravata DM. Stents or surgery? New data on the comparative outcomes of percutaneous coronary intervention and coronary artery bypass graft surgery. Circulation 2008; 118:325-327.
57. Gioia G, Matthai W, Gillin K, Dralle J, Benassi A, Gioia MF, White J. Revascularization in severe left ventricular dysfunction: outcome comparison of drug-eluting stent implantation versus coronary artery by-pass grafting. Catheter Cardiovasc Interv 2007; 70:26-33.
58. Brener SJ, Galla JM, Bryant R III, Ellis SG. Comparison of percutaneous versus surgical revascularization of severe unprotected left main coronary stenosis in matched patients. Am J Cardiol 2008; 101:169-172.
59. Javaid A, Steinberg DH, Buch AN, Corso PJ, Boyce SW, Pinto Slottow TL, et al. Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with drug-eluting stents for patients with multivessel coronary artery disease. Circulation 2007; 116 (11 Suppl):I200-I206.
60. James TN. Small arteries of the heart. Circulation 1977; 56:2-14.
61. Wu TG, Wang L. Angiographic characteristics of the coronary artery in patients with type 2 diabetes. Exp Clin Cardiol 2002; 7:199-200.
62. Greer JC, Bishop SP, James TN. Pathology of small intramural coronary arteries. Path Annu 1979; 14:125-154.
63. Aggarwal A, Schneider DJ, Sobel BE, Dauerman HL. Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. Am J Cardiol 2003; 92:924-929.
64. Du X, Edelstein D, Obici S, Higham N, Zou M-H, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 2006; 116:1071-1080.
65. Sobel BE. The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes. Proc Assoc Am Phys 1999; 111:313-318.
66. Sobel BE, Taatjes DJ, Schneider DJ. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23:1979-1989.
67. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94:2013-2020.
68. Sobel BE. Fibrinolysis and diabetes. Front Biosci 2003; 8:d1085-d1092.
69. Van Belle E, Ketelers R, Bauters C, Perie M, Abolmaali K, Richard F, et al. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: a key determinant of survival in diabetics after coronary balloon angioplasty. Circulation 2001; 103:1218-1224.
70. Sobel BE. Acceleration of restenosis by diabetes: pathogenetic implications. Circulation 2001; 103:1185-1187.
71. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al.; for the OASIS Registry Investigators. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000; 102:1014-1019.
72. Mak K-H, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, et al.; for the GUSTO-I Investigators. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol 1997; 30:171-179.
73. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Herheugt FWA, et al.; for the TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - thrombolysis in myocardial infarction 38. Circulation 2008; 118:1626-1636.
74. Mazeika P, Prasad N, Bui S, Seidelin PH. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J 2003; 145:1013-1021.
75. Schneider DJ, Sobel BE. Diabetes and thrombosis. In: Johnstone MT, Veves A, editors. Contemporary cardiology: diabetes and cardiovascular disease. 2nd ed. Totowa: Humana Press, Inc.; 2005. pp. 107-128.
76. Kendall DM, Sobel BE, Coulston AM, Harmel ALP, McLean BK, Peragallo-Dittko V, et al.; and The Partners Against Insulin Resistance Advisory Panel. The insulin resistance syndrome and coronary artery disease. Coron Artery Dis 2003; 14:335-348. .
77. Merz CN, Buse JB, Tuncer D, Twillman GB. Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol 2002; 40:1877-1881.
78. Friedewald VE, Leiter LA, McGuire DK, Nesto RW, Roberts WC. The editor's roundtable: diabetes mellitus and coronary heart disease. Am J Cardiol 2006; 98:842-856.
79. Kasai T, Miyauchi K, Kurata T, Okazaki S, Kajimoto K, Kubota N, Daida H. Impact of metabolic syndrome among patients with and without diabetes mellitus on long-term outcomes after percutaneous coronary intervention. Hypertens Res 2008; 31:235-241.
80. Selcuk H, Temizhan A, Timur Selcuk M, Sen T, Maden O, Tekeli S, Sasmaz A. Impact of metabolic syndrome on future cardiovascular events in patients with first acute myocardial infarction. Coron Artery Dis 2009; 20:370-375.
81. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359-1367.
82. Derde S, Vanhorebeek I, Van den Bereghe G. Insulin treatment in intensive care patients. Hrm Res 2009; 71:2-11.
83. De La Rosa GDC, Donado JH, Restrepo AH, Quintero AM, Gonzalez LG, Saldarriaga NE, et al. Strict glycemic control in patients hospitalized in a mixed medical surgical intensive care unit: a randomized clinical trial. Critical Care 2008; 12:R120-R129.
84. Pittas AG, Siegel RD, Lau J. Insulin therapy for critically ill hospitalized patients. Arch Intern Med 2004; 164:2005-2011.
85. Malmberg K; for the DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. Br Med J 1997; 314:1512-1515.
86. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P,Waldenstrom A, et al.; for the DIGAMI Study Group. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26:57-65.
87. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al.; DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26:650-661.
88. Mellbin LG, Malmberg K, Waldenstrom A, Wedel H, Ryden L; DIGAMI 2 Investigators. Prognostic implications of hypoglycemic episodes during hospitalization for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial. Heart 2009; 95:721-727.
89. Rowen M, Schneider DJ, Pratley RE, Sobel BE. On rendering continuous glucose monitoring ready for prime time in the cardiac care unit. Coron Artery Dis 2007; 18:405-409.
90. Despres J-P, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien P-J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334:952-957. (Pubitemid 26114161)
91. Clinical Alert from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bypass over Angioplasty for Patients with Diabetes. September 21, 1995.
92. King SB III. Acute myocardial infarction: are diabetics different? J AmColl Cardiol 2000; 35:1513-1515.
93. Sobel BE. Potentiation of vasculopathy by insulin: implications from an NHLBI clinical alert. Circulation 1996; 93:1613-1615.
94. Zhao XQ, Kosinski AS, Barnhart HX, Superko HR, King SB III. Prediction of native coronary artery disease progression following PTCA or CABG in the Emory Angioplasty Versus Surgery Trial. Med Sci Monit 2003; 9:CR48-CR54.
95. Detre KM, Guo P, Holubkov R, Calilff RM, Sopko G, Bach R, et al. Coronary revascularization in Diabetes Patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999; 99:633-640.
96. King SB III. Is surgery preferred for the diabetic with multivessel disease? Surgery is preferred for the diabetic with multivessel disease. Circulation 2005; 112:1500-1515.
97. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009; 373:1190-1197.
98. Kugelmass AD, Cohen DJ, Houser F, Mack M, Simon AW, Battaglia SL, et al. The influence of diabetes mellitus on the practice and outcomes of percutaneous coronary intervention in the community: a report from the HCA database. J Invasive Cardiol 2003; 15:575-577.
99. Gwon HC, Choi SH, Choi BI, Cho SY, Ro YM, Lee WR; KORR Investigators. Percutaneous coronary intervention versus coronary artery bypass grafting for diabetics with multivessel coronary artery disease: the Korean Multicenter Revascularization Registry (KORR). J Korean Med Sci 2005; 20:196-203.
100. Banning AP, Westaby S, Morice MC, Kappetein AP, Mohr FW, Bertis S, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol 2010. [Epub ahead of print]
101. King SB III. The emory angioplasty versus surgery trial (EAST). Semin Interv Cardiol 1999; 4:185-190.
102. The Bypass Angioplasty Revascularization Investigators (BARI). Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation 1997; 96z:1761-1769.
103. Tryzelaar JF, Clough R, Hearne MJ, Hernandez F Jr, Watkins MW, O'Connor GT; for the Northern New England Cardiovascular Disease Study Group. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. J Am Coll Cardiol 2001; 37:1008-1015.
104. Ben-Gal Y, Moshkovitz Y, Nesher N, Uretzky G, Braunstein R, Hendler A, et al. Drug-eluting stents versus coronary artery bypass grafting in patients with diabetes mellitus. Ann Thorac Surg 2006; 82:1692-1697. (Pubitemid 44596267)
105. Weintraub WS, Stein B, Kosinski A, Douglas JS Jr, Ghazzal ZMB, Jones EL, et al. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol 1998; 31:10-19.
106. Van den Goor J, Saxby B, Tijssen J, Wesnes K, de Mol B, Nieuwland R. Improvement of cognitive test performance in patients undergoing primary CABG and other CPB-assisted cardiac procedures. Perfusion 2008; 23:267-273.
107. Selnes OA, Grega MA, Bailey MM, Pham LD, Zeger SL, Baumgartner WA, McKhann GM. Cognition 6 years after surgical or medical therapy for coronary artery disease. Ann Neurol 2008; 63:581-590.
108. Stroobant N, van Nooten G, De Bacquer D, Van Belleghem Y, Vingerhoets G. Neuropsychological functioning 3-5 years after coronary artery bypass grafting: does the pump make a difference? Eur J Cardiothorac Surg 2008; 34:396-401.
109. Hernandez F Jr, Brown JR, Likosky DS, Clough RA, Hess AL, Roth RM, et al. Neurocognitive outcomes of off-pump versus on-pump coronary artery bypass: a prospective randomized controlled trial. Ann Thorac Surg 2007; 84:1897-1903.
110. Perloff JK, Perloff M. Coronary artery bypass: a user's manual. Am J Cardiol 2004; 94:172-177.
111. Daemen J, Kuck KH, Macaya C, LeGrand V, Vrolix M, Carrie D, et al.; ARTSII Investigators. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial.
112. Hillegass W. CAGB versus DES PCI in diabetics with multivessel disease: back to the BARI registry. Catheter Cardiovasc Interv 2009; 73:59-60.
113. King SB III, Mahmud E. Will blocking the platelet save the diabetic? Circulation 1999; 100:2466-2468.
114. Freeman AM, Abbott JD, Jacobs AK, Vlachos HA, Selzer F, Laskey WK, et al. Marked improvements in outcomes of contemporary percutaneous coronary intervention in patients with diabetes mellitus. J Interv Cardiol 2006; 19:475-482.
115. Serruys PW, Ong ATL, van Herwerden Lex A, Sousa JE, Jatene A, Bonnier JJRM, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the arterial revascularization therapies study (ARTS randomized trial). J Am Coll Cardiol 2005; 46:575-581.
116. Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation2 Diabetes (BARI 2D) trial. Circulation 2003; 107:636-642.
117. Fonseca VA. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Am J Med 2007; 120:S18-S25.
118. Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, et al.; for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Hypothesis, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am J Cardiol 2006; 97 (Suppl):9G-19G.
119. The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360:2503-2515.
120. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471.
121. Mulrow CD, Cornell J, Locallo AR. Rosiglitazone: a thunderstorm from scarce and fragile data. Ann Intern Med 2007; 147:585-587.
122. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; 147:578-581.
123. Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, et al.; and the BARI 2D Study Group. The BARI 2D randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation (in press).
124. Farkouh ME, Dangas G, Leon MB, Smith C, Nesto R, Buse JB, et al. Design of the future Revascularization Evaluation in patients with Diabetes mellitus: optimal management of multivessel disease (FREEDOM) trial. Am Heart J 2008; 155:215-223.